Hologic, Inc. (NASDAQ: HOLX) has grown to become a leading developer, manufacturer and supplier of premium diagnostic products, medical
Hologic, Inc. (NASDAQ: HOLX) has grown to become a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products created specifically to address the healthcare needs of women throughout the world.Their comprehensive suite of products spans nine key areas: mammography and breast biopsy; radiation treatment for early-stage breast cancer; cervical cancer screening; treatment for menorrhagia; permanent contraception; osteoporosis assessment; preterm birth risk assessment; mini C-arms for extremity imaging; as well as molecular diagnostic products, including human papillomavirus (HPV) testing and reagents for a variety of DNA and RNA analysis applications. The core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.The complex health issues facing women today deserve and demand the singular dedication of a passionate company committed to doing everything in its power to help women live longer, stronger, healthier lives.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 26, 2008
Cianna Medical
|
Series A | $9M | Health Care | — |
BioLucent has had 1 exits. BioLucent most notable exits include Cianna Medical
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Oct 1, 2018 | Cianna Medical | M&A | Health Care | Detail |